© 1999 by European Society of Cardiology
Copyright © 1999, European Society of Cardiology
The 2.3 kb smooth muscle myosin heavy chain promoter directs gene expression into the vascular system of transgenic mice and rabbits1,2,
aMedizinische Klinik II, University of Lübeck, Lübeck, Germany
bInstitut für Tierzucht und Genetik, University of Veterinary Medicine, Vienna, Austria
cWyeth-Ayerst Research, Princeton, NJ, USA
dDepartment of Anatomy and Embryology, University of Amsterdam, Amsterdam, The Netherlands
* Corresponding author. Tel.: +49-451-500-2732; fax: +49-451-500-6437 franz{at}medinf.mu-luebeck.de
Background: Smooth muscle cells (SMC) are a preferential target for gene therapeutic approaches in atherosclerosis and restenosis. However, the undesirable expression of putative therapeutic genes in tissues other than the vascular wall is a considerable safety limitation for clinical trials, thus requiring the identification of a smooth-muscle-specific promoter sequence. Since the 2.3 kb rabbit Smooth Muscle Myosin Heavy Chain (SMHC) promoter was shown to be transcriptionally active in primary vascular but not visceral or other non-SMC in vitro, this fragment was chosen for in vivo analysis. Methods and Results: Transgenic mice and rabbits were established expressing a luciferase reporter gene under control of the 2.3 kb rabbit SMHC promoter. In contrast to the endogenous expression pattern of the SMHC gene both species revealed light emission predominantly in the arterial system including coronary arteries. Low activities were measured in large veins and the gastrointestinal system. In situ hybridization of murine embryos using a luciferase riboprobe confirmed reporter gene expression in large arteries with no detectable mRNA in the viscera. Unlike adult animals, ectopic luciferase activities were found in ventricular myocardium during murine development ceasing 1 week post partum. Conclusions: In two animal species, the 2.3 kb SMHC promoter appeared to be effective in discriminating between the pathways regulating vascular and visceral smooth muscle gene expression. The vascular-specific expression profile of the 2.3 kb SMHC promoter suggests that the 2.3 kb SMHC promoter contains the regulatory elements necessary for selective gene targeting into vascular SMC of large arteries including coronary arteries in vivo.
KEYWORDS Gene expression; Gene therapy; Smooth muscle; Arteries; Coronary circulation
1 Franz, Mueller, both authors contributed equally.
2 Brem, Katus, both Institutions contributed equally.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. M. Hoggatt, G. M. Simon, and B. P. Herring Cell-Specific Regulatory Modules Control Expression of Genes in Vascular and Visceral Smooth Muscle Tissues Circ. Res., December 13, 2002; 91(12): 1151 - 1159. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Conley Leiomodin and tropomodulin in smooth muscle Am J Physiol Cell Physiol, June 1, 2001; 280(6): C1645 - C1656. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Miano, C. M. Kitchen, J. Chen, K. M. Maltby, L. A. Kelly, H. Weiler, R. Krahe, L. K. Ashworth, and E. Garcia Expression of human smooth muscle calponin in transgenic mice revealed with a bacterial artificial chromosome Am J Physiol Heart Circ Physiol, May 1, 2002; 282(5): H1793 - H1803. [Abstract] [Full Text] [PDF]
|
|